Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 9
1987 12
1988 7
1989 17
1990 16
1991 5
1992 5
1993 13
1994 18
1995 20
1996 39
1997 45
1998 46
1999 71
2000 67
2001 92
2002 91
2003 74
2004 72
2005 75
2006 48
2007 67
2008 56
2009 65
2010 61
2011 84
2012 69
2013 64
2014 70
2015 55
2016 74
2017 65
2018 33
2019 18
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,514 results
Results by year
Filters applied: . Clear all
Page 1
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Cohen JA, et al. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122652 Clinical Trial.
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, Yang X. Zhang J, et al. Cochrane Database Syst Rev. 2017 Nov 27;11(11):CD010968. doi: 10.1002/14651858.CD010968.pub2. Cochrane Database Syst Rev. 2017. PMID: 29178444 Free PMC article. Review.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. Vermersch P, et al. Mult Scler. 2014 May;20(6):705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14. Mult Scler. 2014. PMID: 24126064 Clinical Trial.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J. Kappos L, et al. N Engl J Med. 2015 Oct 8;373(15):1418-28. doi: 10.1056/NEJMoa1501481. N Engl J Med. 2015. PMID: 26444729 Free article. Clinical Trial.
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Hu X, Shang S, Nestorov I, Hasan J, Seddighzadeh A, Dawson K, Sperling B, Werneburg B. Hu X, et al. Br J Clin Pharmacol. 2016 Aug;82(2):380-8. doi: 10.1111/bcp.12968. Epub 2016 May 29. Br J Clin Pharmacol. 2016. PMID: 27060836 Free PMC article. Clinical Trial.
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A. Traboulsee A, et al. BMC Neurol. 2018 Sep 14;18(1):143. doi: 10.1186/s12883-018-1145-x. BMC Neurol. 2018. PMID: 30217172 Free PMC article. Clinical Trial.
Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis.
Faraji F, Hashemi M, Ghiasabadi A, Davoudian S, Talaie A, Ganji A, Mosayebi G. Faraji F, et al. Complement Ther Med. 2019 Aug;45:275-279. doi: 10.1016/j.ctim.2019.04.010. Epub 2019 Apr 23. Complement Ther Med. 2019. PMID: 31331574 Clinical Trial.
1,514 results
Jump to page